An observational study in Hypercholesterolemia, Carotid Intimal Medial Thickness 1 and Seizure, sponsored by Johns Hopkins University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Johns Hopkins University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 41 under way, 11 of them phase 3. Hypercholesterolemia · United States.
Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 18th largest by planned enrollment of the 31 observational ones that give a count, is one of 20 that started in 2016, is one of 31 observational ones, reaches primary completion later than 7 of the 39 other live ones, and was the 242nd registered.
1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Australia, Canada and 1 more country
Ages 18–130
AstraZeneca · Sites in United States, Bulgaria, Canada and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Midwest Center for Metabolic and Cardiovascular Research · Sites in United States
Ages 18–74 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 72 · Phase 3 106 · Phase 4 33
First in 1976; this study’s year is marked. 20 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is below the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.
Median enrollment 120 across the 347 interventional studies, 260 across the 31 observational. Of the 320 that completed or were terminated, 161 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
208 of 379 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 4 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
18 of the studies in Hypercholesterolemia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07619118Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | 2027-05-28 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT06960655Brigham and Women's HospitalImproving Lipid Optimization Quality and Treatment Options in ASCVD | 2026-11-30 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 379 studies in Hypercholesterolemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is being done to evaluate the short term and long term effects of ketogenic diets on measures of cardiovascular health. Such measures include cholesterol levels, blood pressure, weight, and thickening of the blood vessel wall over time. Adults aged 18 or older who are already on a ketogenic diet for at least 12 months or who are interested in beginning on the modified Atkins diet may join.
If participants agree to be in this study, the investigators will ask the participants to do the following things:
At Initial enrollment for both longterm ketogenic diet and new modified Atkins diet participants
At follow-up clinic visits (month 3 and month 6) for new modified Atkins diet participants
At follow-up clinic visits (month 12 and month 24) for new modified Atkins diet participants
Study participants will be drawn from among participants in the Johns Hopkins Adult Epilepsy Diet Center and Johns Hopkins Epilepsy Center who are age 18 or older, with body mass index (BMI) > 18.5, and on a stable antiepileptic drug regimen for > 1 month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults who have been on Modified Atkins or ketogenic diets for over 1 year
Dietary Supplement: Modified Atkins or Ketogenic Diet
Adults who have never been on Modified Atkins or ketogenic diets
Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
Change in carotid artery intima-media thickness (mm) measured by carotid artery ultrasound
Carotid artery ultrasound will be used to measure the change in average intima-media thickness over time with comparisons between baseline and 12 months of diet therapy.
Time frame: Baseline and 12 months post diet implementation
Change in LDL fractions (nmol/L)
The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 12 months of diet therapy.
Time frame: Baseline and 12 months post diet implementation
Change in LDL fractions (nmol/L)
The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 3 months of diet therapy.
Time frame: Baseline and 3 months post diet implementation
Change in apolipoproteins (mg/dL)
The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 3 months of diet therapy.
Time frame: Baseline and 3 months post diet implementation
Change in apolipoproteins (mg/dL)
The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 6 months of diet therapy.
Time frame: Baseline and 6 months post diet implementation
Change in apolipoproteins (mg/dL)
The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 12 months of diet therapy.
Time frame: Baseline and 12 months post diet implementation
Change in apolipoproteins (mg/dL)
The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 24 months of diet therapy.
Time frame: Baseline and 24 months post diet implementation
Change in LDL fractions (nmol/L)
The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 6 months of diet therapy.
Time frame: Baseline and 6 months post diet implementation
Change in LDL fractions (nmol/L)
The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 24 months of diet therapy.
Time frame: Baseline and 24 months post diet implementation
Change in carotid artery intima-media thickness (mm) measured by carotid artery
Carotid artery ultrasound will be used to measure the change in average intima-media thickness over time with comparisons between baseline and 24 months of diet therapy.
Time frame: Baseline and 24 months post diet implementation
Plan to share: No
The record gives a start of Mar 2016, a primary completion of Dec 2026 and a completion of Mar 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.